Compare LAW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | TSHA |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.9M | 1.7B |
| IPO Year | 2021 | 2020 |
| Metric | LAW | TSHA |
|---|---|---|
| Price | $5.27 | $4.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $6.67 | ★ $13.00 |
| AVG Volume (30 Days) | 172.5K | ★ 3.5M |
| Earning Date | 11-04-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,849,000.00 | $9,773,000.00 |
| Revenue This Year | $12.02 | N/A |
| Revenue Next Year | $10.55 | $1,023.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.29 | ★ 17.28 |
| 52 Week Low | $2.45 | $3.46 |
| 52 Week High | $9.11 | $7.30 |
| Indicator | LAW | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 71.60 | 43.34 |
| Support Level | $3.93 | $3.46 |
| Resistance Level | N/A | $4.72 |
| Average True Range (ATR) | 0.23 | 0.26 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 88.50 | 65.02 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.